Patents by Inventor Yoichi Ozawa
Yoichi Ozawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11925639Abstract: Provided is a pharmaceutical composition for treating a tumor, which is used in combination therapy of lenvatinib and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.Type: GrantFiled: February 6, 2018Date of Patent: March 12, 2024Assignee: Eisai R&D Management Co., Ltd.Inventors: Yoichi Ozawa, Yusaku Hori, Kazuhiko Yamada, Hiroshi Kamiyama, Masahiro Matsuki
-
Publication number: 20240075410Abstract: There is provided a gas solution supply apparatus capable of preventing bubbles from being generated in use at a point-of-use even if gas solution to be provided to a point-of-use has a high concentration. The gas solution supply apparatus 1 includes: a gas dissolving unit 4 that dissolves a source gas in a source liquid to produce a first gas solution; a first gas-liquid separator 10 that stores the first gas solution produced and produces a second gas solution through gas-liquid separation of the first gas solution; a pressure reducer 17 that depressurizes the second gas solution produced in the first gas-liquid separator 10; and a second gas-liquid separator 12 that stores the depressurized second gas solution and produces a third gas solution through gas-liquid separation of the second gas solution. The third gas solution is supplied to a point-of-use.Type: ApplicationFiled: August 2, 2023Publication date: March 7, 2024Inventors: Suguru OZAWA, Yuji ARAKI, Yoichi NAKAGAWA, Toshifumi WATANABE, Risa KIMURA, Ryuta KATO
-
Publication number: 20230330081Abstract: Provided is a pharmaceutical composition for treating a tumor, comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxyl-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or its pharmaceutically acceptable salt, which is to be administered in combination with a PD-1 antagonist.Type: ApplicationFiled: October 26, 2021Publication date: October 19, 2023Inventors: Taisuke HOSHI, Yu KATO, Yoichi OZAWA, Satoshi KAWANO, Kotaro KODAMA, Saori MIYANO
-
Publication number: 20220409724Abstract: The present disclosure describes a combination therapy comprising an antagonist of Programmed Death 1 receptor (PD-1), a lenvatinib or a pharmaceutically acceptable salt thereof, and (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide (E7386) or a pharmaceutically acceptable salt thereof,—and the use of the combination therapies for the treatment of a cancer.Type: ApplicationFiled: October 28, 2020Publication date: December 29, 2022Applicants: Eisai R&D Management Co., Ltd., Merck Sharp & Dohme Corp., MSD International GmbHInventors: Yoichi OZAWA, Yasuhiro FUNAHASHI, Yu KATO
-
Patent number: 11369623Abstract: The present invention aims to provide a therapeutic drug for cancer having a superior treatment effect. A cancer treatment using a CBP/catenin inhibitor and an immune checkpoint inhibitor in combination not only increases a treatment effect on cancer, but also enables an effective treatment of cancer patients showing low sensitivity when an immune checkpoint inhibitor is used alone.Type: GrantFiled: June 15, 2016Date of Patent: June 28, 2022Assignees: PRISM Pharma Co., Ltd., Eisai R&D Management Co., Ltd.Inventors: Takenao Odagami, Hiroyuki Kouji, Yoichi Ozawa, Yusaku Hori
-
Publication number: 20190388420Abstract: Provided is a pharmaceutical composition for treating a tumor, which is used in combination therapy of lenvatinib and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.Type: ApplicationFiled: February 6, 2018Publication date: December 26, 2019Applicant: Eisai R&D Management Co., Ltd.Inventors: Yoichi Ozawa, Yusaku Hori, Kazuhiko Yamada, Hiroshi Kamiyama, Masahiro Matsuki
-
Publication number: 20180244808Abstract: Provided is a method capable of efficiently producing a modified diene-based rubber, and a rubber composition and a tire with excellent low hysteresis loss property, durability, etc. The method for producing a modified diene-based rubber of this disclosure comprises: performing modification by adding a modifier into a solution of a diene-based rubber as raw material obtained by dissolving a diene-based rubber as raw material in a solvent, and removing the solvent and reacting the modifier with the diene-based rubber as raw material while exerting a mechanical shear force, to thereby generate a modified diene-based rubber. The rubber composition of this disclosure uses a modified diene-based rubber produced with the method for producing a modified diene-based rubber of this disclosure. The tire of this disclosure uses the rubber composition of this disclosure.Type: ApplicationFiled: August 1, 2016Publication date: August 30, 2018Applicant: BRIDGESTONE CORPORATIONInventors: Toshihiro UCHIYAMA, Hajime KONDO, Yoichi OZAWA
-
Publication number: 20180185395Abstract: The present invention aims to provide a therapeutic drug for cancer having a superior treatment effect. A cancer treatment using a CBP/catenin inhibitor and an immune checkpoint inhibitor in combination not only increases a treatment effect on cancer, but also enables an effective treatment of cancer patients showing low sensitivity when an immune checkpoint inhibitor is used alone.Type: ApplicationFiled: June 15, 2016Publication date: July 5, 2018Applicants: PRISM Pharma Co., Ltd., EISAI R&D MANAGEMENT CO., LTD.Inventors: Takenao Odagami, Hiroyuki Kouji, Yoichi Ozawa, Yusaku Hori
-
Patent number: 9969812Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.Type: GrantFiled: December 19, 2016Date of Patent: May 15, 2018Assignee: Eisai R&D Management Co., Ltd.Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino, Masahiko Katayama
-
Patent number: 9644052Abstract: In general the present invention provides a functionalized polymer prepared by a process comprising the steps of preparing a pseudo-living polymer by polymerizing conjugated monomer with a lanthanide-based catalyst, and reacting the pseudo-living polymer with a functionalizing agent defined by the formula (I) A-R1—Z?? (I) where R1 is a divalent bond or divalent organic group comprising from 0 to about 20 carbon atoms, A is a substituent that will undergo an addition reaction with a pseudo-living polymer, and Z is a substituent that will react or interact with silica or carbon black reinforcing fillers, with the proviso that A, R1, and Z are substituents that will not protonate a pseudo-living polymer.Type: GrantFiled: March 23, 2015Date of Patent: May 9, 2017Assignee: Bridgestone CorporationInventors: Yoichi Ozawa, H. Jerrold Miller, Koji Masaki, Koichi Morita, Tatsuo Fujimaki, Tetsuya Omura, Takuo Sone, Iwakazu Hattori
-
Patent number: 9623705Abstract: The invention provides a method for producing a modified conjugated diene (co)polymer, the method including comprising: a modification reaction step including causing an organic silane compound to react with a conjugated diene (co)polymer having an active site at the active site, the organic silane compound having a characteristic group for forming a silanol group through hydrolysis and, in the vicinity of the characteristic group, (i) a functional group which binds the organic silane compound to the conjugated diene (co)polymer via addition to or substitution at the active site and which promotes reaction between the silanol group and a reinforcing filler after the addition or substitution reaction, or (ii) a functional group which promotes reaction between the silanol group and a reinforcing filler, and a hydrolyzation step performed after the modification reaction step; a modified conjugated diene (co)polymer having, at a molecular end of the conjugated diene (co)polymer, a silanol group, and a functionalType: GrantFiled: March 10, 2009Date of Patent: April 18, 2017Assignee: BRIDGESTONE CORPORATIONInventors: Ken Tanaka, Noriko Mori, Yuki Itoh, Yoichi Ozawa, Ryuji Nakagawa, Junko Matsushita, Shigeaki Matsuo, Kouji Masaki, Fumihiro Shiraishi, Fuminori Oota
-
Publication number: 20170100367Abstract: The invention features methods and kits for use in treating cancer in a patient in need thereof by administering eribulin or a pharmaceutically-acceptable salt thereof (e.g., eribulin mesylate) prior to a second agent.Type: ApplicationFiled: May 27, 2015Publication date: April 13, 2017Applicant: Eisai R&D Management Co., Ltd.Inventors: Makoto ASANO, Bruce A. LITTLEFIELD, Junji MATSUI, Martin OLIVO, Yoichi OZAWA, Yanke YU
-
Publication number: 20170096493Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.Type: ApplicationFiled: December 19, 2016Publication date: April 6, 2017Applicant: Eisai R&D Management Co., Ltd.Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino, Masahiko Katayama
-
Patent number: 9527921Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.Type: GrantFiled: April 14, 2016Date of Patent: December 27, 2016Assignee: Eisai R&D Management Co., Ltd.Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino, Masahiko Katayama
-
Publication number: 20160347858Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.Type: ApplicationFiled: April 14, 2016Publication date: December 1, 2016Applicant: Eisai R&D Management Co., Ltd.Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino
-
Publication number: 20150259452Abstract: In general the present invention provides a functionalized polymer prepared by a process comprising the steps of preparing a pseudo-living polymer by polymerizing conjugated monomer with a lanthanide-based catalyst, and reacting the pseudo-living polymer with a functionalizing agent defined by the formula (I) A-R1—Z??(I) where R1 is a divalent bond or divalent organic group comprising from 0 to about 20 carbon atoms, A is a substituent that will undergo an addition reaction with a pseudo-living polymer, and Z is a substituent that will react or interact with silica or carbon black reinforcing fillers, with the proviso that A, R1, and Z are substituents that will not protonate a pseudo-living polymer.Type: ApplicationFiled: March 23, 2015Publication date: September 17, 2015Applicants: JSR CORPORATION, BRIDGESTONE CORPORATIONInventors: Yoichi OZAWA, H. Jerrold MILLER, Koji MASAKI, Koichi MORITA, Tatsuo FUJIMAKI, Tetsuyo OHUMURA, Takuo SONE, Iwakazu HATTORI
-
Patent number: 9056925Abstract: A process for producing a modified conjugated diene based polymer includes a step (a) of reacting a silicon compound with a conjugated diene based polymer having an active end so that the reaction takes place at the active end, the silicon compound having a protected primary amino group in the molecule thereof and a silicon atom to which a hydrocarbyloxy group and a reactive group are bonded, to thereby modify the active end, and a step (b) of performing condensation reaction, in the presence of a titanium compound serving as a titanium-based condensation-accelerating agent. A rubber composition contains the modified diene polymer, and a tire is produced from the rubber composition.Type: GrantFiled: October 25, 2007Date of Patent: June 16, 2015Assignees: BRIDGESTONE CORPORATION, JSR CORPORATIONInventors: Ken Tanaka, Kouji Masaki, Yoichi Ozawa, Eiji Suzuki, Christine M. Rademacher, Terrence E. Hogan, Takuo Sone, Takaomi Matsumoto
-
Patent number: 9033014Abstract: This invention relates to a rubber composition including a polyisoprene rubber having a very high cis-1,4-bond content and having an excellent balance between dynamic properties and processability, and more particularly to a rubber composition comprising as a rubber component (A) a synthetic polyisoprene rubber having a cis-1,4-bond content of not less than 99.0%, a 3,4-bond content of not more than 0.5% and a Mooney viscosity ML1+4 (100° C.) of 20-110 and (B) a natural rubber.Type: GrantFiled: June 25, 2004Date of Patent: May 19, 2015Assignee: Bridgestone CorporationInventors: Eiju Suzuki, Yoichi Ozawa
-
Patent number: 8987362Abstract: In general the present invention provides a functionalized polymer prepared by a process comprising the steps of preparing a pseudo-living polymer by polymerizing conjugated monomer with a lanthanide-based catalyst, and reacting the pseudo-living polymer with a functionalizing agent defined by the formula (I) A-R1—Z??(I) where R1 is a divalent bond or divalent organic group comprising from 0 to about 20 carbon atoms, A is a substituent that will undergo an addition reaction with a pseudo-living polymer, and Z is a substituent that will react or interact with silica or carbon black reinforcing fillers, with the proviso that A, R1, and Z are substituents that will not protonate a pseudo-living polymer.Type: GrantFiled: December 10, 2013Date of Patent: March 24, 2015Inventors: Yoichi Ozawa, H. Jerrold Miller, Koji Masaki, Koichi Morita, Tatsuo Fujimaki, Tetsuyo Omura, Takuo Sone, Iwakazu Hattori
-
Patent number: 8962752Abstract: This invention relates to a rubber composition being excellent in the low heat buildup and fracture properties (resistance to crack growth). and more particularly to a rubber composition, characterized by compounding 10-100 parts by mass of an inorganic filler and/or carbon black based on 100 parts by mass of a rubber component including not less than 10 mass % of a modified conjugated diene-based polymer having a cis-1,4 bond content of not less than 90% and a vinyl bond content of not more than 1.2% and a primary amino group. In this case, the modified conjugated diene-based polymer is obtained by (1) reacting the predetermined conjugated diene-based polymer having an active terminal with a compound having two or more predetermined functional groups and (2) further reacting the resulting product with a compound having a primary amino group.Type: GrantFiled: April 22, 2014Date of Patent: February 24, 2015Assignee: Bridgestone CorporationInventors: Junko Matsushita, Yoichi Ozawa